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Abstract
Objective: Frontotemporal lobar degeneration (FTLD) is the second most
prevalent dementia in young patients and is characterized by the presence of
two main protein aggregates in the brain, tau (FTLD-Tau) or TDP43 (FTLD-
TDP), which likely require distinct pharmacological therapy. However, specific
diagnosis of FTLD and its subtypes remains challenging due to largely overlap-
ping clinical phenotypes. Here, we aimed to assess the clinical performance of
novel cerebrospinal fluid (CSF) biomarkers for discrimination of FTLD and its
pathological subtypes. Methods: YKL40, FABP4, MFG-E8, and the activities of
catalase and specific lysosomal enzymes were analyzed in patients with
FTLD-TDP (n = 30), FTLD-Tau (n = 20), AD (n = 30), DLB (n = 29), and
nondemented controls (n = 29) obtained from two different centers. Models
were validated in an independent CSF cohort (n = 188). Results: YKL40 and
catalase activity were increased in FTLD-TDP cases compared to controls.
YKL40 levels were also higher in FTLD-TDP compared to FTLD-Tau. We iden-
tified biomarker models able to discriminate FTLD from nondemented controls
(MFG-E8, tTau, and Ab42; 78% sensitivity and 83% specificity) and non-FTLD
dementia (YKL40, pTau, p/tTau ratio, and age; 90% sensitivity, 78% speci-
ficity), which were validated in an independent cohort. In addition, we identi-
fied a biomarker model differentiating FTLD-TDP from FTLD-Tau (YKL40,
MFGE-8, bHexA together with bHexA/tHex and p/tTau ratios and age) with
80% sensitivity and 82% specificity. Interpretation: This study identifies CSF
protein signatures distinguishing FTLD and the two main pathological subtypes
with optimal accuracy (specificity/sensitivity > 80%). Validation of these mod-
els may allow appropriate selection of cases for clinical trials targeting the accu-
mulation of Tau or TDP43, thereby increasing their efficiency and facilitating
the development of successful therapies.
Introduction
Frontotemporal lobar degeneration (FTLD) is the second
most prevalent dementia in patients below 65 years old1,2
and has the worst life expectancy among non-prion
dementia.3 Two main pathological subtypes have been
described based on the proteinopathy found in the brain:
around half of the cases develop aggregates of the
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microtubule-associated protein tau (FTLD-Tau), while
the other half are characterized by cytoplasmic inclusions
of the transactivator regulatory DNA-binding protein 43
(TDP43, FTLD-TDP).4 These two main pathologies likely
require distinct pharmacological therapy, and thus, dis-
crimination of both subtypes is strongly needed. How-
ever, the clinical presentation of the FTLD pathological
subtypes is heterogeneous and overlapping.5 So far, there
are still no effective early biomarkers available to discrim-
inate FTLD and its two main pathological subtypes, ham-
pering the selection of appropriate patients for clinical
trials targeting the specific proteinopathy (i.e., Tau or
TDP43).6,7
Most biomarker studies have been performed in patho-
logically heterogeneous populations.8 The few studies ana-
lyzing antemortem cerebrospinal fluid (CSF) with known
underlying neuropathology have revealed several candi-
date biomarkers, such as the pTau181 to tau ratio, which
discriminates FTLD-TDP from FTLD-Tau cases with
approximately 80% sensitivity and 60% specificity.9–11
Despite these promising results, their specificity is far
from optimal, most of the identified markers are awaiting
further validation and their diagnostic accuracy remains
to be evaluated.
In order to unravel novel specific biomarkers for FTLD
subtypes, we previously mapped and validated changes in
the proteome of antemortem CSF of well-characterized
FTLD patients with confirmed tau or TDP43 pathology
and nondemented controls.12 In this study, we externally
validated and assessed the clinical performance of the
identified novel CSF biomarkers (chitinase-3-like protein
1 [CHI3L1 or YKL-40], milk fat globule-EGF factor 8
protein [MFG-E8], fatty acid-binding protein 4 [FABP4],
catalase activity, and specific lysosomal enzymes’ activity),
as single biomarkers or combined, in discriminating
FTLD and its different pathological subtypes using two
independent cohorts biobanked at the Emory University
and Milan University Hospital Policlinico.
Methods
Human CSF samples
CSF material was obtained from the Emory University
(n = 100, USA) and Milan University Hospital Policlinico
(n = 45, Italy) (discovery cohort, Table 1). FTLD patients
with an underlying TDP43 pathology (FTLD-TDP,
n = 30) were selected based on autopsy (n = 8) and
C9orf72/GRN mutations (n = 15).13,14 Diagnostic groups
were enriched with CSF from patients with FTLD-Plus
syndromes that reflect high correlation with a specific
neuropathology. Thus, the FTLD-TDP group was
enriched with FTLD patients with amyotrophic lateral
sclerosis (FTLD-ALS, n = 7), associated with TDP43
pathology.15 FTLD cases with tau neuropathology (FTLD-
Tau, n = 20) were selected based on autopsy (n = 2),
MAPT mutations (n = 2),6 and familial history of
autopsy confirmed FTLD-Tau (n = 1). The FTLD-Tau
group was also enriched with CSF from patients with
FTLD-Plus syndromes related to tau pathology such as
progressive supranuclear palsy (FTLD-PSP, n = 10) or
corticobasal syndrome (FTLD-CBS, n = 5).16,17 Notewor-
thy, six FTLD-Tau and six FTLD-TDP patients had a pos-
itive AD CSF biomarker profile (low CSF b-amyloid 1–42
(Ab42) and high p or t-Tau level, applying local labora-
tory standards), suggesting potential AD copathology in
those cases. Non-demented healthy controls (CON,
n = 29, 4 of them with positive CSF AD biomarker pro-
file) and patients with other types of dementia, such as
AD (n = 30) and DLB (n = 29), were also selected to test
the specificity of the biomarker signatures to FTLD. An
additional independent CSF cohort was used for valida-
tion of the resulting CSF protein biomarker signatures
(validation cohort: [subjective cognitive decline
(SCD) = 59, FTLD-TDP = 42, FTLD-Tau = 50, AD = 17,
and DLB = 20]), consisting of samples recruited at the
Erasmus Medical Center (MC) and the VU Medical Cen-
ter (VUmc; Table 1).
All participants underwent standard neurological and
cognitive assessments and diagnosis was assigned accord-
ing to consensus criteria.18–24 The control group of the
validation cohort were labeled during a multidisciplinary
consensus meeting as SCD when they presented with sub-
jective cognitive complaints, but objective cognitive and
laboratory investigations (including AD CSF biomarkers)
were normal and thus comparable to controls (CON).
Non-demented healthy control or SCD cases did not meet
criteria for mild cognitive impairment and had no signs
of inflammatory or neurodegenerative disorders, or family
history of neurodegenerative diseases. All CSF samples of
all cohorts were stored in agreement with the JPND-BIO-
MARKAPD guidelines.25 Demographic data, concentra-
tion of CSF Ab42, t-Tau, pTau, and type of diagnosis of
all cases used in each cohort and the biomarkers mea-
sured are summarized in Table.1. The studies were
approved by the Institutional Ethical Review Boards of
each center. Informed consent was obtained from all sub-
jects or their authorized representatives.
Biomarker analysis
CSF levels of the biomarkers were measured using specific
immunoassays that have been previously validated for
CSF analysis12 (Data S1). Intra- and interassays CVs were
calculated using two CSF pools as quality controls, result-
ing in 1.8% and 10% for YKL-40, 3.1% and 9.5% for
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FABP4, 10.8% and 24.2% for MFG-E8, and 3.1% and
13.7% for catalase activity. The levels of AD-related
biomarkers (total and phosphorylated tau [t-Tau and
pTau181]) were analyzed in the corresponding sample col-
lection center using the commercially available kits
(Emory: INNO-BIA AlzBio3; Milan: Innotest Ab(1-42),
hTAUAg, phosphor-Tau(181P); Fujiribo, Ghent,
Belgium, both using the same antibodies) as previously
described.9,26 The levels of neurofilament light change
(NfL) were measured in a subset of cases within the
validation cohort using a validated immunoassay ELISA
of UmanDiagnostics (Umea, Sweden) as previously
described.27 All biomarkers were analyzed by a single
experienced technician blinded to the clinical groups.
Effects of preanalytical factors
The effects of age, sex, and storage duration on CSF ana-
lytes were assessed by statistical evaluation of the results
as described below. The effect of freeze–thaw cycles was
experimentally determined for YKL40, MFG-E8, and cata-
lase activity by freezing and thawing independent CSF
samples (n = 2–3) up to four times, leaving the samples
each time at least 2 hours at room temperature, and next
store at 80°C for at least 12 h.
Statistical analysis
Statistical analyses were performed using SPSS (Chicago,
IL, USA). The influence of different preanalytical variables
on biomarker levels was analyzed by linear regression
after normalizing skewed data using two-step transforma-
tion.28,29 Between-group analyses of demographic vari-
ables were performed using the Student’s t-test or
Pearson’s chi-square test in normally distributed data.
Non-Gaussian distributed data were analyzed using the
Mann–Whitney test. In the discovery cohort, difference in
the biomarker levels between the clinical groups was eval-
uated by ANCOVA using normalized values and includ-
ing either center and age or length of storage as covariate
followed by Fisher’s least significant difference (LSD,
equivalent to Mann–Whitney U test for adjusted means).
Noteworthy, not every differentially expressed marker
necessarily has discriminatory power in a classification
Table 1. Descriptive statistics of demographics by diagnostic groups
CON FTLD-TDP FTLD-Tau AD DLB
Cohort 1 (Emory + Milan)
n (M/F) 29 (14/15) 30 (18/12) 20 (13/7) 30 (15/15) 29 (15/14)
Age, years (mean  SD) 62 (15) 66 (7) 65 (10) 69 (8) 68 (8)
n (Emory/Milan) 20/9 20/10 20/0 20/10 20/9
Ab1–42 (pg/mL) 408 (307)
a,c, d,e 230 (452)b 176 (101)b 218 (211)b 298 (279)b
t-Tau (pg/mL) 46 (36)a 78 (114)a 43 (35)a 171 (156)b,c,d,e 43 (199)a
pTau (pg/mL) 18 (12)a,e 23 (21)a,e 18 (14)a 72 (46)b,c,d,e 33 (19)a,b,c
FTLD subgroups 8 autopsy 2 autopsy
15 mutations 2 mutations
7 FTLD-ALS 1 family history
10 PSP
5 CBS
Cohort 2 (VUmc + ErasmusMC)
n (M/F) 59 (32/27) 42 (23/19) 50 (26/24) 17 (9/8) 20 (17/3)
Age, years (mean  SD) 59 (10) 60(8) 64 (9) 64 (6) 63 (5)
Ab1–42 (pg/mL) 983 (342)
a,c, d,e 874 (328)a,b 795 (335)a,b 461 (137)b,c,d,e 648 (483)a,b
t-Tau (pg/mL) 249 (106)a,c 353 (137)a,b 290 (182)a 622 (237)b,c,d,e 299 (118)a
pTau (pg/mL) 45 (20)a 38 (15)a,e 39 (21)a 84 (26)b,c,d,e 53 (24)a
FTLD subgroups 15 autopsy 3 autopsy
21 mutations 5 mutations
6 FTLD-ALS 22 PSP
20 CBS
CON, nondemented controls; FTLD, frontotemporal lobar degeneration; AD, Alzheimer’s disease; DLB, dementia with Lewy body; PSP, progressive
supranuclear palsy; CBS, corticobasal syndrome; n, number of cases; M, Male; F, female.
aP < 0.05 compared to AD.
bP < 0.05 compared to CON.
cP < 0.05 compared to FTLD-TDP.
dP < 0.05 compared to FTLD-Tau.
eP < 0.05 compared to DLB.
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exercise.30 Thus, we next used multivariate stepwise back-
ward logistic regression based on likelihood ratio to find
the classification signature that gives maximum predictive
performance in the demarcation of the specific diagnostic
groups including all the CSF markers analyzed and age.
The resulting predicting probabilities were used to assess
the diagnostic value of biomarker combination using
receiver operator characteristic (ROC). Multilayer percep-
tron analysis was used to validate the models by ran-
domly selecting subset of samples from the whole cohort.
Areas under the curve (AUC), sensitivity, and specificity
values were calculated. The performance of the models
was classified as poor (AUC:0.6–0.7), moderate (AUC =
0.7–0.8), good (AUC = 0.8–0.9), and optimal (AUC =
0.9–1). To further validate the biomarker models, we next
analyzed the corresponding biomarker combinations in
the independent validation cohort by logistic regression
and ROC analysis. For models that could not be further
tested in the validation cohort, data were reanalyzed using
support vector machine (SVM), which randomly splits
the original samples of analysis into training and valida-
tion sets (70–30%, respectively). Values with P < 0.05
were considered significant.
Results
Demographic and preanalytical effects
No difference in age or sex was observed between FTLD
pathological subtypes (Table 1). Samples from the Emory
cohort had a shorter storage time and patients had a
lower age compared to those obtained from Milan
(P < 0.001). We observed that the overall levels of all
biomarkers with the exception of FABP4 were higher in
samples collected at Emory University (Table S1).
Freeze–thaw cycles did not influence the levels of YKL-
40, MFG-E8, or catalase activity (Fig. S1), except for
lysosomal activities, which change only after two freeze–
thaw cycles.31 Longer storage time was associated with
decreased levels of MFG-E8 (P < 0.0001), as well as the
activities of catalase (P < 0.0001) and all lysosomal
enzymes (P < 0.01). Patient age influenced only the levels
of YKL-40 (P < 0.01) and FABP4 (P < 0.01). Sex did not
influence any of the biomarkers analyzed (Table S2).
In summary, we observed that age influenced the levels
of YKL-40 and FABP4. The center in which samples were
collected had a strong influence on all the CSF biomark-
ers analyzed and the length of storage negatively influ-
enced MFG-E8 concentration and the activities of catalase
and lysosomal enzymes. Thus, analysis of the data was
performed always correcting for center and either length
of storage or age when applicable.
Change in levels of YKL-40, MFG-E8, and
catalase activity in CSF across different
diagnostic groups
YKL40 was increased in the overall FTLD group compared
to nondemented controls (P < 0.01) and was higher in
FTLD-TDP compared to FTLD-Tau cases (P < 0.05).
YKL40 was also increased in FTLD-TDP compared to DLB
and nondemented controls (P < 0.0001), but did not differ
from those in AD (Fig. 1A). ROC analysis showed that CSF
YKL-40 levels had a moderate performance discriminating
nondemented healthy controls (CON) from the overall
FTLD patients (AUC: 0.74; 95% CI: 0.62–0.85, P < 0.0001)
or FTLD-TDP subtype (AUC: 0.78; 95% CI: 0.67–0.90,
P < 0.0001, Fig. 2D) but did not reach sufficient sensitiv-
ity/specificity values (<80%, Table 2).
The levels of MFG-E8 were decreased in the overall
FTLD group compared to AD (P < 0.05). No significant
difference was observed between FTLD-TDP and FTLD-
Tau. MFG-E8 levels were especially lower in FTLD-TDP
patients compared to AD (P < 0.05, Fig. 1B). MFG-E8
Figure 1. YKL-40, MFG-E8 and catalase activity in CSF were changed across the different diagnostic groups. Dot plot displays the uncorrected
values of YKL40 (A) MFG-E8 (B) and the activity of catalase (C) in CSF for each clinical group (FTLD-TDP in blue and FTLD-Tau in orange). Median
and interquartile range are represented *P < 0.05; ***P < 0.001. Abbreviations: n.s., nonsignificant; CSF, cerebrospinal fluid; CON, healthy
nondemented controls; TDP, TAR DNA-binding protein 43; AD, Alzheimer’s disease; DLB, dementia with Lewy bodies.
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did not show enough diagnostic performance on discrim-
inating FTLD from AD.
Catalase activity in CSF was increased in FTLD and
FTLD-TDP compared to controls (P < 0.05) and DLB
patients (P < 0.05; Fig. 1C). Catalase activity could only
discriminate FTLD from nondemented controls with poor
performance (AUC: 0.64; P = 0.05, Fig. 2A, Table 2).
The levels of FABP4 as well as the activity of the differ-
ent lysosomal enzymes in CSF were not changed between
the different diagnostic groups (Fig. S2). Differences in
biomarker levels between the non-FTLD dementia groups
were also observed (Fig. 1A–C).
Specific CSF protein signatures discriminate
FTLD and its pathological subtypes
CSF biomarkers discriminating FTLD from CON
Multivariate stepwise backward regression revealed that
combination of MFG-E8 together with tTau and Ab42
could discriminate control cases from FTLD patients
(FTLD vs. CON model) with optimal performance (AUC:
0.90, 95% CI: 0.83–0.98, P < 0.0001) leading to 78%
sensitivity and 83% specificity. This performance was better
to that observed for any of the individual markers within
the model (Fig. 2A, Table 2). These results were confirmed
by multilayer perceptron analysis (AUC: 0.91).
CSF biomarkers discriminating FTLD from non-
FTLD dementia cases
Combination of YKL-40 with pTau, the p/tTau ratio and
age could discriminate FTLD cases from patients with
non-FTLD dementia (AD and DLB) with optimal perfor-
mance (AUC: 0.86, 95% CI: 0.78–0.93, P < 0.0001) lead-
ing to 90% sensitivity and 78% specificity. This
performance was better to that observed for any of the
individual markers within the model (Fig. 2B, Table 2).
These results were confirmed by multilayer perceptron
analysis (AUC: 0.86).
CSF biomarkers discriminating FTLD-TDP from
FTLD-Tau
Combination of YKL40, MFG-E8, activity of bHexA, and
the bHexA/tHex activity ratio together with p/tTau ratio
Figure 2. Receiver operating curves (ROC) of the different models discriminating specific diagnostic groups in the discovery cohort. (A) ROC
curves of the individual markers or the corresponding biomarker combination (MFG-E8, tTau, and Ab42) discriminating FTLD from CON. (B) ROC
curves of the individual markers or the corresponding biomarker combination (YKL40, pTau, p/tTau, and age) discriminating FTLD from non-FTLD
dementia (AD, DLB). (C) ROC curves of the individual markers or the corresponding biomarker combination (YKL40, MFG-E8, p/tTau ratio, bHexA
activity, b/tHexA, and age) discriminating FTLD-TDP from FTLD-Tau. (D) ROC curves of the individual markers or the corresponding biomarker
combination discriminating FTLD-TDP from CON (YKL40, MFG-E8, and catalase activity) with and without center as interaction factor.
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and age could discriminate FTLD-TDP from FTLD-Tau
(TDP vs. Tau model) with an accuracy of 0.87 (95% CI
AUC: 0.77–0.97, P < 0.0001), and a sensitivity and speci-
ficity of 80% and 81%, respectively (Fig. 2C, Table 2). Such
results were confirmed by multilayer perceptron analysis
(AUC: 0.9). This performance was better to that observed
for the p/tTau ratio alone (AUC: 0.78; 95% CI: 0.65–0.91,
P = 0.001, 80% sensitivity and 59% specificity, Fig. 2C,
Table 2), the marker showing the strongest discrimination
between FTLD-TDP and FTLD-Tau to date.9,10
CSF biomarkers discriminating FTLD-TDP from
CON
Combination of YKL-40, MFG-E8, and catalase activity
including center as an interaction factor could discrimi-
nate control cases from FTLD-TDP patients (TDP vs.
CON model) with optimal performance (AUC: 0.92, 95%
CI: 0.84–0.97, P < 0.0001, Fig. 2D) leading to 90% sensi-
tivity and 83% specificity. Adding tau markers, either
alone or as ratio, did not improve the sensitivity or speci-
ficity of the model. Importantly, removing center as an
interaction factor decreased specificity to 76% (AUC:
0.88, 95% CI AUC: 0.80–0.97, P < 0.0001, Fig. 2D,
Table 2). These results were confirmed by multilayer per-
ceptron analysis (AUC: 0.88).
CSF biomarker signatures discriminating CON from
FTLD-Tau were not identified.
Validation of the biomarker models
We next tested how well the generated models could be val-
idated in independent validation cohort (Table 3). We
observed that the “FTLD vs. CON” model (MFG-E8, tTau,
and Ab42) could again discriminate FTLD from CON cases
with optimal performance (AUC: 0.93, 95% CI: 0.89–0.97,
P < 0.0001; with 88% sensitivity and 85% specificity
(Fig. 3A; Table 3). Using a subset of cases for which NfL
measurements were available (FTLD = 92, CON = 28), we
observed that the FTLD vs. CON model (AUC:0.94;
P < 0.0001) performed similar to NfL alone (AUC:0.94
P < 0.0001, Fig. S3), a non-disease specific marker that
optimally discriminate FTLD cases from controls.27,32–34
The “FTLD vs. non-FTLD dementia” model (pTau,
t/pTau ratio, YKL40 and age) could again optimally
discriminate FTLD cases from non-FTLD dementia cases
(AD and DLB) in the validation cohort (AUC: 0.93, 95%
CI: 0.88–0.98, P < 0.0001) achieving 91% sensitivity and
84% specificity (Fig. 3B; Table 3). The “FTLD-TDP vs.
CON” model (YKL-40, MFG-E8, and catalase activity)
was also validated in the new independent cohort (AUC:
0.94, 95% CI: 0.90–0.99, P < 0.0001) with 90% sensitivity
and 86% specificity (Fig. 3C; Table 3).
Most of the samples of the validation cohort had
already undergone more than two freeze–thaw cycles,
which affect the overall activity values of tHexA and
bHexA.31 The number of samples available in which the
activity of such enzymes could be optimally measured
(TDP = 12, FTLD-Tau = 6) was too small and thus the
“TDP vs. Tau” model could not be validated in an inde-
pendent cohort. However, analysis of the discovery cohort
using supporting vector machine (SVM), an alternative
statistical approach that randomly split the cohort into
training and testing sets, reported similar results (AUC:
0.93) with average error rates of 22.4% and 21.3% for the
training and testing test.
Discussion
Biomarkers discriminating FTLD pathological subtypes
are strongly needed for the selection of patients in drug
trials targeting the specific proteinopathies.6,7 We have
assessed and validated the clinical performance of novel
CSF biomarkers identified previously12 for discrimination
of FTLD pathological subtypes and nondemented controls
using two independent CSF cohorts coming from differ-
ent centers. The main findings were the identification of
four novel CSF biomarker signatures able to discriminate:
(1) FTLD from non-demented controls (FTLD vs. CON
model: MFG-E8, tTau, and Ab42), (2) FTLD from other
dementia (FTLD vs. non-FTLD dementia model: YKL-40,
pTau, and p/tTau ratio) and (3) the main FTLD patho-
logical subtypes (TDP vs. Tau model: YKL40, MFG-E8,
activity of bHexA, bHexA/tHex ratio, p/tTau ratio, and
age).
In agreement with previous studies, CSF YKL40 was
increased in FTLD and AD compared to controls.35–37
FTLD-TDP had the highest YKL-40 values, which were
comparable to those observed in AD patients, but differ-
ent to those observed in CON, FTLD-Tau, or DLB. These
findings are partially in agreement with our previous
study in which higher levels were also observed in the
FTLD-Tau group.12 Importantly, FTLD-Tau encompasses
tauopathies with different etiologies such as FTLD-MAPT,
PSP, PiD, and CBD. While our previous proteomics-
based study analyzed mainly FTLD-Tau cases with MAPT
mutations,12 the current study was performed with a
more heterogeneous FTLD-Tau group including also spo-
radic CBS and PSP cases, which may explain the observed
discrepancies. Indeed, recent studies have highlighted that
CSF biomarkers (e.g., pTau) can differ between familial
and sporadic FTLD cases that develop the same underly-
ing neuropathology.38,39 Thus, this data also highlights
the impact that the heterogeneity within each FTLD sub-
type can have on the CSF biomarker profile. CSF YKL-40
was also increased in different acute inflammatory
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disorders indicating that YKL-40 is an inflammatory mar-
ker likely reflecting astrogliosis.40–44 Thus, the different
levels of YKL-40 levels across different pathological
groups may indicate a different inflammatory response.
We also analyzed the levels of MFG-E8, a molecule that
has been shown to mediate microglia phagocytosis.45
Despite the fact that MFG-E8 was increased in AD cases
compared to both FTLD subtypes, it did not discriminate
those clinical groups. Recent data has shown that Ab can
induce the release of MFG-E8,46 and therefore, the higher
levels of MFG-E8 may reflect the higher amyloid load of
AD patients that is rarely seen in FTLD cases.4
Catalase activity in CSF was increased in FTLD-TDP
compared to non-demented controls, which challenges
our previous findings in which the activity of catalase was
specially decreased in the FTLD group.12 The time length
of sample storage before analysis (which negatively influ-
ences CSF catalase activity) as well as the higher FTLD
heterogeneity of this study may explain the discrepancy
observed. Some cases within the nondemented controls or
the FTLD-TDP groups showed remarkably lower values
of catalase than the rest of the samples (i.e., catalase
<2.5 U/L), which are likely explained by the center of col-
lection (Milan) or time of storage rather than by a














FTLD (n = 49) vs. CON (n = 23)
MFG-E8 na na na 0.55 (0.405-0.702) na na 0.428 0.0004 0.005
tTau na na na 0.62 (0.487–0.747) na na 0.111 0.068 <0.0001
Ab42 264 71 69 0.75 (0.632–0.859) 2.29 0.42 0.001 0.010 <0.0001
FTLD vs. CON model4 0.686 78 83 0.90 (0.827–0.976) 4.59 0.27 <0.0001
FTLD (n = 49) vs. non-FTLD dementia (n = 57)
YKL40 na na na 0.60 (0.491–0.708) na na 0.071 0.004 0.021
pTau 29.1 77 67 0.80 (0.702–0.877) 2.3 0.3 <0.0001 0.044 <0.0001
p/tTau na na na 0.62 (0.512–0.728) na na 0.034 2.33 0.008
Age na na na 0.61 (0.503–0.719) na na 0.047 0.079 0.010
FTLD vs. non-FTLD
dementia model5
0.3903 90 78 0.86 (0.781–0.930) na na <0.0001
FTLD-TDP (n = 29) vs. FTLD -Tau (n = 20)
p/t Tau ratio 0.285 80 59 0.77 (0.641–0.906) 2 0.3 0.001 7.67 0.006
YKL40 na na na 0.64 (0.476–0.794) na na 0.109 0.009 0.049
MFG-E8 na na na 0.57 (0.411–0.729) na na 0.406 0.001 0.027
bHexA na na na 0.57 (0.404–0.737) na na 0.414 0.012 0.021
bHexA/tHex na na na 0.54 (0.370–0.708) na na 0.651 44.330 0.041
Age na na na 0.52 (0.336–0.696) na na 0.851 0.133 0.036
TDP vs. Tau model6 0.4563 80 81 0.87 (0.772–0.969) 4.2 0.2 <0.0001
FTLD-TDP (n = 29) vs. CON (n = 30)
YKL40 25.35 80 62 0.78 (0.665–0.901) 2.1 0.3 <0.0001 0.017 0.001
MFG-E8 na na na 0.44 (0.283–0.589) na na 0.396 0.001 0.003
Catalase na na na 0.62 (0.474–0.761) na na 0.122 0.430 0.024
TDP vs. CON model7 0.4431 90 76 0.88 (0.796–0.965) 3.8 0.1 <0.0001
AUC, area under the curve; CI, confident interval; LR, likelihood ratio; CON, nondemented controls; FTLD, frontotemporal lobar degeneration.
n.a: not applicable due to the lack of significance.




4FTLD vs. CON model: y = 2.94  0.0004*MFGE8 + 0.07*tTau  0.01*Ab42.
5FTLD vs. non-FTLD dementia models: y = 6.621  0.004*YKL40 + 0.044*pTau + 2.33*p/tTau ratio + 0.79*Age.
6TDP vs. Tau model: y = 14.659  0.009*YKL40 + 0.001*MFGE8  0.012*bHexA activity + 44.33*bHexA/tHex activity ratio + 7.671*p/tTau
ratio + 0.133*Age.
7TDP vs. CON model: y = 3.193 + 0.017*YKL40  0.001*MFGE8 + 0.43*catalase activity.
Markers/models achieving sufficient biomarker performance are highlighted in bold.
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specific pathophysiological characteristic (i.e., TDP-ALS).
Catalase is an antioxidant enzyme, and thus, the observed
increase activity may reflect a compensatory mechanism
to counteract the oxidative stress present in different
dementia such as AD or FTLD.47,48
We next assessed whether our protein dataset could
reveal specific combination of markers discriminating
non-demented controls and FTLD subtypes. We observed
that combination of MFG-E8 together with CSF tTau
and Ab42 could discriminate FTLD patients from














FTLD (n = 90) vs. CON (n = 55)
MFG-E8 5975 81 69 0.81 (0.734–0.884) 2.61 0.28 <0.0001 0.001 <0.0001
tTau 262.5 71 59 0.68 (0.592–0.765) 1.73 0.49 <0.0001 0.019 <0.0001
Ab42 886 66 65 0.67 (0.577–0.755) 1.89 0.52 0.001 0.003 0.008
FTLD vs. CON model 0.594 88 85 0.93 (0.894–0.971) 5.87 0.14 <0.0001
FTLD (n = 91) vs. non-FTLD dementia models (n = 37)
YKL40 273 72 70 0.74 (0.644–0.833) 2.40 0.40 <0.0001 0.011 0.001
pTau 45.5 78 71 0.82 (0.729–0.911) 2.69 0.31 <0.0001 0.083 <0.0001
p/tTau 0.134 70 60 0.68 (0.577–0.788) 1.75 0.50 0.001 13.04 0.017
Age na na na 0.55 (0.444–0.646) na na 0.423 0.062 0.113
FTLD vs. non-FTLD
dementia model
0.636 91 84 0.93 (0.884–0.975) 5.69 0.11 <0.0001
FTLD-TDP (n = 42) vs. CON (n = 57)
YKL40 259.93 79 70 0.78 (0.690–0.881) 2.63 0.30 <0.0001 0.016 <0.0001
MFG-E8 6069.5 80 79 0.83 (0.745–0.907) 3.81 0.25 <0.0001 0.001 <0.0001
Catalase 4.44 70 62 0.71 (0.614–0.815) 1.84 0.48 <0.0001 0.413 0.151
TDP vs. CON model 0.297 90 86 0.94 (0.898–0.989) 6.43 0.12 <0.0001
AUC, area under the curve; CI, confident interval; LR, likelihood ratio; CON, nondemented controls; FTLD, frontotemporal lobar degeneration,
n.a, nonapplicable.




Markers/models achieving sufficient biomarker performance are highlighted in bold.
Figure 3. Receiver operating curves (ROC) of the different models discriminating specific diagnostic groups in the validation cohort. (A–C) ROC
curves of the (A) FTLD vs. CON model (MFG-E8, tTau, and Ab42), (B) the FTLD vs. non-FTLD dementia models (YKL40, pTau, p/tTau, and age) and
(C) the FTLD-TDP vs. CON model (YKL40, MFG-E8, and catalase activity) discriminating corresponding patients in the discovery (green line) and
validation (blue line) cohorts. Abbreviations: FTLD, frontotemporal lobar degeneration; CON, healthy nondemented controls; TDP, TAR DNA-
binding protein 43; AD, Alzheimer’s disease.
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nondemented controls with 78% sensitivity and 82%
specificity, which was validated in a larger independent
cohort achieving sensitivity and specificity values >80%.
Most of the potential FTLD CSF biomarkers studied to
date (e.g., tau, tdp43) did not achieve enough sensitivity
or specificity.8,49–52 In a subset of cases, we observed that
the FTLD vs. CON model achieved similar performance
to that observed for NfL alone. However, CSF NfL is a
nonspecific disease biomarker that is upregulated in other
disorders such as AD.27,32,34 Importantly, recent studies
showed that the ratio between NfL and the soluble b frag-
ment of amyloid precursor protein (sAPPb)53 or the
combination of TDP43 with p/tTau ratio54 could opti-
mally discriminate FTLD patients from CON in a large
cohort, promising data that need to be replicated in inde-
pendent cohorts. An additional challenge in clinical prac-
tice is the differential diagnosis of dementia. Noteworthy,
up to 30% of FTLD cases are misdiagnosed with other
disorders, especially AD.55 Several studies have shown that
ratios with AD CSF biomarkers (i.e., pTau/Ab42 or tTau/
Ab42) can discriminate FTLD from AD with perfor-
mances over 80%.38,56 In this study, we identified a model
able to discriminate FTLD from a general group of non-
FTLD dementia (AD and DLB) with 91% sensitivity and
84% specificity using pTau, p/tTau ratio and YKL40.
Taken together, the biomarker combinations described
above may aid on the optimal diagnosis of FTLD within
the dementia spectrum, the first step toward diagnosing
the specific FTLD subtypes.
We next identified a model able to discriminate the
two main pathological subtypes of FTLD (TDP vs.Tau
model: YKL40, MFG-E8, bHexA, bHexA/tHex, p/tTau
ratio, and age) with a sensitivity and specificity of 80%
and 82%. The p/tTau ratio has already been shown to be
a reproducible biomarker discriminating both FTLD
pathological subtypes with sensitivity and specificity val-
ues around 82% and 62%, respectively,9,10 as also
observed in the current study. Interestingly, the addition
of age, YKL40, and MFG-E8 together with the activity of
bHexA and its ratio increased the specificity to 81%.
These outcomes were not affected by the center in which
samples were collected, and similar results were obtained
when data were reanalyzed using SVM. These data reveal
a potential biomarker model discriminating FTLD patho-
logical subtypes with enough sensitivity and specificity
values according to biomarker guidelines (>80%).57 Such
model could be highly relevant since it may facilitate the
appropriate selection of cases (FTLD-TDP or FTLD-Tau)
for clinical trials targeting the specific protein aggregates
(TDP43 or Tau) once FTLD diagnosis is made, ultimately
easing the development of disease-modifying therapies.
However, it is important to highlight that the achieved
sensitivity and specificity still did not reach excellent
performance (over 90%) and that validation of this model
in independent cohorts remains to be performed.
We identified a model that could discriminate FTLD-
TDP patients from controls with 90% sensitivity and 76%
specificity, which was also validated in a larger indepen-
dent cohort. Despite the clinical utility of this model
might be limited, the optimal validation of the model in
an independent cohort further supports the validity of the
data obtained in this study. Importantly, we observed that
the specificity of this model increased up to 83% when
center of was included as an interaction factor, indicating
a strong influence of preanalytical confounding factors
(e.g., differences in freeze–thaw cycles, spinning condi-
tions, length of storage, tube filling, brand collection
tube). This data stresses the importance of unraveling and
controlling for those preanalytical factors within biomar-
ker studies.25
Strikingly, some of the biomarkers that were not signif-
icantly changed between two specific diagnostic groups
(i.e., MFG-E8) contributed to discriminate those patients
within the predicting models. Thus, the results of this
study also highlight the importance of selecting biomarker
candidates based not only on the fold-change between the
groups of interest but also based on their effect in combi-
nation with other markers using unbiased predicting
models. These models may reflect not only changes in
protein concentration but also association of different
proteins to the specific phenotype within each patient,
ultimately reducing interindividual variability and increas-
ing diagnostic performance. Thus, multivariate models
might be especially helpful for diagnosis of complex dis-
orders with strong comorbidity such as neurodegenerative
dementia.
Limitations
The data revealed in this study are promising but impor-
tant limitations also apply. Some of the models revealed
in this study are based on complex formulas including six
markers and thus its final implementation in clinical
practice might be challenging. However, development of
highly sensitive targeted multiplex assays may facilitate
the validation of such biomarkers signatures.58,59 Note-
worthy, biomarkers outcomes may differ across different
stages of the disease. Despite there is no well-established
tools to optimally define the disease stage of FTLD cases
yet,60 the CSF samples used in this study were mostly col-
lected at the same stage of the disease, within 1–3 years
from symptoms onset. Thus, it would be also relevant to
analyze the performance of the revealed models in cases
at more advance stages of the disease. In addition, the
lack of autopsy confirmation in some of the selected cases
(i.e., those with clinical syndromes highly predictive of
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FTLD-Tau and FTLD-TDP) may have led to the inclusion
of cases with AD copathology55 influencing the resulting
diagnostic performances. However, inclusion of cases with
potential AD comorbidity may provide also a more
heterogeneous scenario that better resembles clinical prac-
tice. Lastly, although the cohorts analyzed in this study
are relatively large compared to earlier pathology-con-
firmed CSF biomarker studies, we acknowledge that the
sample size remains small and therefore results should
still be replicated in larger cohorts, specially the biomar-
ker model that optimally discriminated FTLD-TDP
patients from FTLD-Tau. However, considering that the
three other models unraveled within this study (FTLD vs.
CON, FTLD vs. non-FTLD dementia, and TDP vs. CON)
were replicated in a large independent cohort, we expect
to further validate the TDP vs. Tau biomarker signature
as soon as more samples become available. Whether com-
binations of the markers analyzed in this study aid in the
diagnosis of non-FTLD dementia remains to be evaluated.
Conclusion
This study reveals different biomarker models based on
the p/tTau ratio and a panel of different neuroinflamma-
tory and lysosomal CSF biomarkers that can discriminate
FTLD from nondemented controls and other dementia as
well as the main FTLD pathological subtypes with opti-
mal accuracy (specificity/sensitivity >80%). These models
may allow appropriate selection of cases for clinical trials
targeting the specific proteinopathy, thereby facilitating




MC developed the study concept and design, and was
responsible of acquisition of data, statistical analysis and
interpretation, and drafting/revision of the manuscript.
NE, LB, and KW carried out the immunoassay analyses,
and SP carried out the enzyme activities. JvS, YP, TB,
and DG participated in acquisition and interpretation
data and the critical revision of the manuscript. WH
participated in acquisition, analysis and interpretation of
data, and in the critical revision of the manuscript. CT
developed the study concept and design, and was
involved in acquisition of data, analysis and interpreta-
tion, drafting/revision of the manuscript, and study
supervision. All authors read and approved the final
manuscript.
Conflict of Interest
MC, NE, LB, KW, SP, DG, TB, and YP report no
disclousures.
WH reports grants from Alzheimer’s Drug Discovery
Foundation, grants from National Institute of Health, and
grants from American Federation for Aging Research, dur-
ing the conduct of the study; personal fees from ViveBio,
LLC, personal fees from Locks Law Firm, grants from
Fujirebio US, nonfinancial support from Avid Radiophar-
maceutical, personal fees from Abbvie, personal fees from
Hoffman LaRoche, personal fees from AARP, Inc, personal
fees from Interpleader Law, outside the submitted work; In
addition, Dr. Hu has a patent US No. 9,618,522 issued.
CT reports personal fees from advisory board of Fujire-
bio and Roche, nonfinancial support from research con-
sumables from ADxNeurosciences, other from performed
contract research or received grants from Janssen preven-
tion center, Boehringer, EIP farma, Roche and Probiodrug,
PeopleBio, Charles River, outside the submitted work.
Data Availability
The datasets used and/or analyzed during the current
study are available from the corresponding author on rea-
sonable request.
Ethics Approval and Consent to
Participate
The studies were approved by the Institutional Ethical Review
Boards of each center. Informed consent was obtained from
all subjects or their authorized representatives.
References
1. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The
prevalence of frontotemporal dementia. Neurology
2002;58:1615–1621.
2. Brunnstr€om H, Gustafson L, Passant U, Englund E.
Prevalence of dementia subtypes: a 30-year retrospective
survey of neuropathological reports. Arch Gerontol Geriatr
2009;49:146–149.
3. Brodaty H, Seeher K, Gibson L. Dementia time to death: a
systematic literature review on survival time and years of
life lost in people with dementia. Int Psychogeriatr
2012;24:1034–1045.
4. Mackenzie IRA, Neumann M, Bigio EH, et al.
Nomenclature and nosology for neuropathologic subtypes
of frontotemporal lobar degeneration: an update. Acta
Neuropathol 2010;119:1–4.
5. Irwin DJ, Trojanowski JQ, Grossman M. Cerebrospinal
fluid biomarkers for differentiation of frontotemporal
1172 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
CSF Biomarkers for FTLD and Its Subtypes M. del Campo et al.
lobar degeneration from Alzheimer’s disease. Front Aging
Neurosci 2013;5:6.
6. Irwin DJ, Cairns NJ, Grossman M, et al. Frontotemporal
lobar degeneration: defining phenotypic diversity through
personalized medicine. Acta Neuropathol 2015;129:469–
491. [cited 2015 Jan 2]. Available from: http://www.ncbi.
nlm.nih.gov/pubmed/25549971
7. International Conference on Frontotemporal Dementias
2016. Fluid NfL Shines, Tau PET Dims, in the Hunt for
FTD Biomarkers|ALZFORUM. [date unknown]; Available
from: http://www.alzforum.org/news/conference-coverage/
fluid-nfl-shines-tau-pet-dims-hunt-ftd-biomarkers
8. Oeckl P, Steinacker P, Feneberg E, Otto M. Cerebrospinal
fluid proteomics and protein biomarkers in frontotemporal
lobar degeneration: current status and future perspectives.
Biochim Biophys Acta – Proteins Proteomics
2014;1854:757–768.
9. Hu WT, Watts K, Grossman M, et al. Reduced CSF
p-Tau181 to Tau ratio is a biomarker for FTLD-TDP.
Neurology 2013;81:1945–1952.
10. Borroni B, Benussi A, Archetti S, et al. Csf p-tau181/tau
ratio as biomarker for TDP pathology in frontotemporal
dementia. Amyotroph Lateral Scler Frontotemporal
Degener 2014;16:86–91.
11. Pijnenburg YAL, Verwey NA, van der Flier WM, et al.
Discriminative and prognostic potential of cerebrospinal
fluid phosphoTau/tau ratio and neurofilaments for
frontotemporal dementia subtypes. Alzheimer’s Dement
2015;1:505–512.
12. Teunissen CE, Elias N, Koel-Simmelink MJA, et al. Novel
diagnostic cerebrospinal fluid protein biomarkers for
pathologic subtypes of frontotemporal dementia identified
by proteomics. Alzheimer’s Dement 2016;2:86–94.
13. Baker M, Mackenzie IR, Pickering-Brown SM, et al.
Mutations in progranulin cause tau-negative
frontotemporal dementia linked to chromosome 17.
Nature 2006;442:916–919.
14. Renton AE, Majounie E, Waite A, et al. A hexanucleotide
repeat expansion in C9ORF72 is the cause of chromosome
9p21-linked ALS-FTD. Neuron 2011;72:257–268.
15. Neumann M, Sampathu DM, Kwong LK, et al.
Ubiquitinated TDP-43 in frontotemporal lobar
degeneration and amyotrophic lateral sclerosis. Science
2006;314:130–133.
16. Ingelsson M, Ramasamy K, Russ C, et al. Increase in the
relative expression of tau with four microtubule binding
repeat regions in frontotemporal lobar degeneration and
progressive supranuclear palsy brains. Acta Neuropathol
2007;114:471–479.
17. Dickson DW, Bergeron C, Chin SS, et al. Office of rare
diseases neuropathologic criteria for corticobasal
degeneration. J Neuropathol Exp Neurol 2002;61:935–946.
18. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and
management of dementia with Lewy bodies: third report
of the DLB Consortium. Neurology 2005;65:1863–1872.
19. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal
lobar degeneration: a consensus on clinical diagnostic
criteria. Neurology 1998;51:1546–1554.
20. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of
revised diagnostic criteria for the behavioural variant of
frontotemporal dementia. Brain 2011;134(Pt 9):2456–2477.
21. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the
diagnosis of corticobasal degeneration. Neurology
2013;80:496–503.
22. Litvan I, Agid Y, Calne D, et al. Clinical research criteria
for the diagnosis of progressive supranuclear palsy
(Steele-Richardson-Olszewski syndrome): report of the
NINDS-SPSP international workshop. Neurology
1996;47:1–9.
23. Jack CR, Albert MS, Knopman DS, et al. Introduction to
the recommendations from the National Institute on
Aging-Alzheimer’s Association workgroups on diagnostic
guidelines for Alzheimer’s disease. Alzheimer’s Dement
2011;7:257–262.
24. McKhann GM, Knopman DS, Chertkow H, et al. The
diagnosis of dementia due to Alzheimer’s disease:
recommendations from the National Institute on Aging-
Alzheimer’s Association workgroups on diagnostic
guidelines for Alzheimer’s disease. Alzheimer’s Dement
2011;7:263–269.
25. Del Campo M, Mollenhauer B, Bertolotto A, et al.
Recommendations to standardize preanalytical
confounding factors in Alzheimer’s and Parkinson’s disease
cerebrospinal fluid biomarkers: an update. Biomark Med
2012;6:419–430.
26. Carecchio M, Fenoglio C, Cortini F, et al. Cerebrospinal
fluid biomarkers in progranulin mutations carriers. J
Alzheimer’s Dis 2011;27:781–790.
27. Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical
value of neurofilament and phospho-tau/tau ratio in the
frontotemporal dementia spectrum. Neurology 2018a;90:
e1231–e1239.
28. Templeton GF. A two-step approach for transforming
continuous variables to normal: implications and
recommendations for IS research. Commun Assoc Inf Syst
2011;28:41–59.
29. Templeton GF, Burney LL. Using a two-step
transformation to address non-normality from a business
value of information technology perspective. J Inf Syst
2017;31:149–164.
30. Strbenac D, Mann GJ, Yang JYH, Ormerod JT. Differential
distribution improves gene selection stability and has
competitive classification performance for patient survival.
Nucleic Acids Res 2016;44:e119.
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 1173
M. del Campo et al. CSF Biomarkers for FTLD and Its Subtypes
31. Persichetti E, Chiasserini D, Parnetti L, et al. Factors
influencing the measurement of lysosomal enzymes activity
in human cerebrospinal fluid. PLoS ONE 2014;9:e101453.
32. Zetterberg H, Skillb€ack T, Mattsson N, et al. Association of
cerebrospinal fluid neurofilament light concentration with
Alzheimer disease progression. JAMA Neurol 2016;73:60.
33. Skillb€ack T, Farahmand B, Bartlett JW, et al. CSF
neurofilament light differs in neurodegenerative diseases
and predicts severity and survival. Neurology
2014;83:1945–1953.
34. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid
neurofilament concentration reflects disease severity in
frontotemporal degeneration. Ann Neurol 2014;75:116–126.
35. Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a
novel prognostic fluid biomarker for preclinical
Alzheimer’s disease. Biol Psychiatry 2010;68:903–912.
36. Alcolea D, Carmona-Iragui M, Suarez-Calvet M, et al.
Relationship between b-secretase, inflammation and core
cerebrospinal fluid biomarkers for Alzheimer’s disease. J
Alzheimer’s Dis 2014;42:157–167.
37. Antonell A, Mansilla A, Rami L, et al. Cerebrospinal fluid
level of YKL-40 Protein in preclinical and prodromal
Alzheimer’s disease. J Alzheimer’s Dis. 2014;42:901–908.
38. Lleo A, Irwin DJ, Illan-Gala I, et al. A 2-step cerebrospinal
algorithm for the selection of frontotemporal lobar
degeneration subtypes. JAMA Neurol 2018;75:738–745.
39. Irwin DJ, Lleo A, Xie SX, et al. Ante mortem cerebrospinal
fluid tau levels correlate with postmortem tau pathology in
frontotemporal lobar degeneration. Ann Neurol
2017;82:247–258.
40. Canto E, Tintore M, Villar LM, et al. Chitinase 3-like 1:
prognostic biomarker in clinically isolated syndromes.
Brain 2015;138(Pt 4):918–931.
41. Comabella M, Fernandez M, Martin R, et al.
Cerebrospinal fluid chitinase 3-like 1 levels are associated
with conversion to multiple sclerosis. Brain
2010;133:1082–1093.
42. Modvig S, Degn M, Roed H, et al. Cerebrospinal fluid
levels of chitinase 3-like 1 and neurofilament light chain
predict multiple sclerosis development and disability after
optic neuritis. Mult Scler J 2015;21:1761–1770.
43. Martinez MAM, Olsson B, Bau L, et al. Glial and neuronal
markers in cerebrospinal fluid predict progression in
multiple sclerosis. Mult Scler J 2015;21:550–561.
44. Canto E, Reverter F, Morcillo-Suarez C, et al. Chitinase 3-
like 1 plasma levels are increased in patients with
progressive forms of multiple sclerosis. Mult Scler J
2012;18:983–990.
45. Fuller AD, Van Eldik LJ. MFG-E8 regulates microglial
phagocytosis of apoptotic neurons. J Neuroimmune
Pharmacol 2008;3:246–256. [cited 2016 Jan 25].
46. Neniskyte U, Brown GC. Lactadherin/MFG-E8 is essential
for microglia-mediated neuronal loss and phagoptosis
induced by amyloid b. J Neurochem 2013;126:312–317.
47. Swerdlow R, Burns J, Khan SM. The Alzheimer’s disease
mitochondrial cascade hypothesis. J Alzheimer’s Dis
2010;20(Suppl 2):265–279.
48. Carmona M, Portero-otin M, Naudı A, et al. Type-
dependent oxidative damage in frontotemporal lobar
degeneration : cortical astrocytes are targets of oxidative
damage. J Alzheimer’s Dis 2008;67:1122–1136.
49. Suarez-Calvet M, Dols-Icardo O, Llado A, et al. Plasma
phosphorylated TDP-43 levels are elevated in patients with
frontotemporal dementia carrying a C9orf72 repeat
expansion or a GRN mutation. J Neurol Neurosurg
Psychiatry 2013;43:1–8.
50. Hu WT, Chen-Plotkin A, Grossman M, et al. Novel CSF
biomarkers for frontotemporal lobar degenerations.
Neurology 2010;75:2079–2086.
51. Kuiperij HB, Versleijen AAM, Beenes M, et al. Tau rather
than TDP-43 proteins are potential cerebrospinal fluid
biomarkers for frontotemporal lobar degeneration
subtypes: a pilot study. J Alzheimer’s Dis 2017;55:585–595.
52. Meeter LH, Dopper EG, Jiskoot LC, et al. Neurofilament
light chain: a biomarker for genetic frontotemporal
dementia. Ann Clin Transl Neurol 2016;3:623–636.
53. Alcolea D, Vilaplana E, Suarez-Calvet M, et al. CSF
sAPPb, YKL-40, and neurofilament light in frontotemporal
lobar degeneration. Neurology 2017;89:178–188.
54. Bourbouli M, Rentzos M, Bougea A, et al. Cerebrospinal
fluid TAR DNA-binding protein 43 combined with tau
proteins as a candidate biomarker for amyotrophic lateral
sclerosis and frontotemporal dementia spectrum disorders.
Dement Geriatr Cogn Disord 2017;44:144–152.
55. Forman MS, Farmer J, Johnson JK, et al. Frontotemporal
dementia: clinicopathological correlations. Ann Neurol
2006a;59:952–962.
56. Rivero-Santana A, Ferreira D, Perestelo-Perez L, et al.
Cerebrospinal fluid biomarkers for the differential diagnosis
between Alzheimer’s disease and frontotemporal lobar
degeneration: systematic review, HSROC analysis, and
confounding factors. J Alzheimer’s Dis 2017;55:625–644.
57. The Ronald and Nancy Reagan Research Institute of the
Alzheimer’s Association and the National Institute on
Aging Working Group 123. Consensus report of the
working group on: “molecular and biochemical markers of
Alzheimer ‘s disease”. Neurobiol Aging 1998;19:109–116.
58. Christiansson L, Mustjoki S, Simonsson B, et al. The use
of multiplex platforms for absolute and relative protein
quantification of clinical material. EuPA Open Proteomics
2014;3:37–47.
59. Lewczuk P, Kornhuber J, Vanderstichele H, et al.
Multiplexed quantification of dementia biomarkers in the
CSF of patients with early dementias and MCI: a
multicenter study. Neurobiol Aging 2008;29:812–818.
60. Premi E, Gualeni V, Costa P, et al. Looking for measures
of disease severity in the frontotemporal dementia
continuum. J Alzheimer’s Dis 2016;52:1227–1235.
1174 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
CSF Biomarkers for FTLD and Its Subtypes M. del Campo et al.
Supporting Information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
Figure S1. Effect of freeze–thaw on the concentration of
YKL40 (A), MFG-E8 (B), and catalase activity (C) in
CSF. Each line represents a different CSF sample. Data
represents the % of change in the biomarker concentra-
tion/activity. Most of samples remained within acceptable
+ 20% range (gray dash lines) according to guidelines.25
Figure S2. Dot plot of the levels of FABP4 (A) and the
activity of HexA (B), b-HexA (C), a-GLA (D) in CSF dis-
played for each clinical group (FTD-TDP in blue and
FTD-Tau in orange).
Figure S3. Receiver operating curves (ROC) of the CON
vs. FTLD model and NfL in the validation cohort.
Table S1. Demographic data, overall CSF values and col-
lection/storage protocols by center
Table S2. Relationship between CSF biomarker values
and demographic variables calculated by linear regression
Data S1. Supplementary methods
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